2. Academic Validation
  3. Pilot study of jadomycin B pharmacokinetics and anti-tumoral effects in zebrafish larvae and mouse breast cancer xenograft models

Pilot study of jadomycin B pharmacokinetics and anti-tumoral effects in zebrafish larvae and mouse breast cancer xenograft models

  • Can J Physiol Pharmacol. 2022 Nov 1;100(11):1065-1076. doi: 10.1139/cjpp-2022-0152.
Brendan T McKeown 1 2,  Nicholas J Relja 3,  Steven R Hall 1,  Simon Gebremeskel 4,  Jeanna M MacLeod 3,  Chansey J Veinotte 5,  Leah G Bennett 3,  Leanne B Ohlund 6,  Lekha Sleno 6,  David L Jakeman 3 7,  Jason N Berman 5 8 9,  Brent Johnston 2 4 10,  Kerry B Goralski 1 2 3 5
Affiliations

Affiliations

  • 1 Department of Pharmacology, Faculty of Medicine, Dalhousie University, Halifax, NS, B3H 4R2, Canada.
  • 2 Beatrice Hunter Cancer Research Institute, Halifax, NS, B3H 4R2, Canada.
  • 3 Faculty of Health, College of Pharmacy, Dalhousie University, Halifax, NS, B3H 4R2, Canada.
  • 4 Department of Microbiology & Immunology, Faculty of Medicine, Dalhousie University, Halifax, NS, B3H 4R2, Canada.
  • 5 Division of Pediatric Hematology/Oncology, Department of Pediatrics, IWK Health Centre, Halifax, NS, B3K 6R8, Canada.
  • 6 Chemistry department/CERMO-FC, Faculty of Sciences, Université du Québec à Montréal, Montréal, QC, H2X 2J6, Canada.
  • 7 Department of Chemistry, Faculty of Science, Dalhousie University, Halifax, NS, B3H 4R2, Canada.
  • 8 Children's Hospital of Eastern Ontario Research Institute and Department of Pediatrics, University of Ottawa, Ottawa, ON, K1H 5B2, Canada.
  • 9 Department of Pediatrics, Faculty of Medicine, Dalhousie University, Halifax, NS, B3H 4R2, Canada.
  • 10 Department of Pathology, Faculty of Medicine, Dalhousie University, Halifax, NS, B3H 4R2, Canada.
PMID: 35985040 DOI: 10.1139/cjpp-2022-0152
Abstract

Despite numerous therapeutic options, multidrug resistance (MDR) remains an obstacle to successful breast Cancer therapy. Jadomycin B, a natural product derived from Streptomyces venezuelae ISP5230, maintains cytotoxicity in MDR human breast Cancer cells. Our objectives were to evaluate the pharmacokinetics, toxicity, anti-tumoral, and anti-metastatic effects of jadomycin B in zebrafish larvae and mice. In a zebrafish larval xenograft model, jadomycin B significantly reduced the proliferation of human MDA-MB-231 cells at or below its maximum tolerated dose (40 µm). In female Balb/C mice, a single intraperitoneal dose (6 mg/kg) was rapidly absorbed with a maximum serum concentration of 3.4 ± 0.27 µm. Jadomycin B concentrations declined biphasically with an elimination half-life of 1.7 ± 0.058 h. In the 4T1 mouse mammary carcinoma model, jadomycin B (12 mg/kg every 12 h from day 6 to 15 after tumor cell injection) decreased primary tumor volume compared to vehicle control. Jadomycin B-treated mice did not exhibit weight loss, nor significant increases in biomarkers of impaired hepatic (alanine aminotransferase) and renal (creatinine) function. In conclusion, jadomycin B demonstrated a good safety profile and provided partial anti-tumoral effects, warranting further dose-escalation safety and efficacy studies in MDR breast Cancer models.

Keywords

breast cancer; cancer du sein; jadomycin B; jadomycine B; mouse; pharmacocinétique; pharmacokinetics; poisson-zèbre; souris; toxicity; toxicité; zebrafish.

Figures
Products